C-Reactive Protein and Uric Acid Levels in Patients with Psoriasis

Isha,; Jain, Vineet; Lal, Harbans

doi:10.1007/s12291-011-0132-4

Cited by 48 publications

(56 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, increased concentration of uric acid was accompanied by increased serum level of C-reactive protein. [202]. Hyperuricemia has also been reported in psoriatic arthritis [203].…”

Section: Uric Acidmentioning

confidence: 92%

See 1 more Smart Citation

Biochemical markers of psoriasis as a metabolic disease

Gerkowicz

Pietrzak

Szepietowski

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Psoriasis is a chronic immune mediated inflammatory skin disease with a population prevalence of 2-3%. In recent years, psoriasis has been recognized as a systemic disease associated with metabolic syndrome or its components such as: obesity, insulin resistance, hypertension and atherogenic dyslipidemia. Many bioactive substances have appeared to be related to metabolic syndrome. Based on current literature, we here discuss the possible role of adiponectin, leptin, ghrelin, resistin, inflammatory cytokines, plasminogen activator inhibitor 1, uric acid, C-reactive protein and lipid abnormalities in psoriasis and in metabolic syndrome.

show abstract

“…Furthermore, increased concentration of uric acid was accompanied by increased serum level of C-reactive protein. [202]. Hyperuricemia has also been reported in psoriatic arthritis [203].…”

Section: Uric Acidmentioning

confidence: 92%

“…It has been suggested that serum uric acid should be monitored in patients with psoriasis and metabolic syndrome [200][201][202]. However, a prospective study is required in order to determine if the prevention or treatment of hyperuricemia may affect the development of metabolic syndrome or the course of psoriasis.…”

Section: Uric Acidmentioning

confidence: 99%

Biochemical markers of psoriasis as a metabolic disease

Gerkowicz

Pietrzak

Szepietowski

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…Our findings are in concordance with that of several previous studies conducted separately and involving relatively small patient populations. 6,11,13 According to them enhanced inflammation induces the development of atherogenic dyslipidemic profile in psoriasis patients by modulating the lipoprotein lipase activity via antilipoprotein lipase antibodies. In addition, atherogenic complexes of autoantibodies to oxidized LDL are generated in response to an oxidative inflammatory effect which enhances the accumulation of LDL in the endothelial wall and thereby enhances the CVD risk in psoriasis patients.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, as best of our knowledge, previous studies on psoriasis patients have not included systemic inflammation, oxidative stress and dyslipidemia in a single setting. [11][12][13] Therefore, the present work aims to evaluate the levels of c-reactive protein (CRP), MDA, lipid profile and Apo B/A1 ratio in active psoriasis patients and to determine their role in prediction of CVD risk in same population.…”

Section: Introductionmentioning

confidence: 99%

Systemic inflammation, oxidative stress and apolipoprotein B/A1 ratio in active psoriasis: bridging an apparent paradox

et al. 2015

View full text Add to dashboard Cite

Background: Psoriasis is characterized by systemic increase of inflammation and oxidative stress. In addition, increased incidence of dyslipidemia in dermatological disorders is also in alarming phase. It is conceivable that association of inflammation, oxidative stress and dyslipidemia enhances the future the risk of cardiovascular disease (CVD) in psoriasis patients. The main of the study is to estimate the marker of systemic inflammation, oxidative stress, plasma lipid profile and apolipoprotein levels in psoriasis patients and to determine their role in predicting CVD risk in psoriasis.Methods: The study population consist of subjects categorized into two groups; Group I: Healthy controls and Group II: Psoriasis patients (n= 25 in each group). Erythrocyte malondialdehyde (MDA), plasma C-reactive protein (CRP) and lipid profile along with apolipoprotein B and A1 were measured and statistically analyzed using standard methods.Results: Plasma CRP, total cholesterol, triglycerides, LDL-cholesterol and MDA levels were significantly high (p<0.05) in patient group as compared to healthy controls. HDL-cholesterol levels were altered insignificantly (p<0.1) in patient group. Plasma Apo B/Apo A1 ratio were increased significantly (p<0.01) in patient groups as compared to controls.Conclusions: Thus, enhanced inflammation, oxidative stress along with increase in Apo B, A1 and its ratio authenticates the fact that these markers are more efficient in prediction of CVD risk in psoriasis patients than conventional lipid profile parameters.

show abstract

“…C-reactive protein -CRP) i kwasu moczowego w surowicy u pacjentów z łuszczycą przed leczeniem i po 12 tygodniach terapii. Po zastosowaniu leczenia stę-żenie CRP zmniejszyło się o 50%, a redukcja stężenia kwasu moczowego nastąpiła u prawie 80% pacjentów [48]. Powyższe obserwacje dały podstawy do sformułowania teorii, że łuszczyca, która jest chorobą związaną ze zwiększeniem szybkości proliferacji komórek naskórka (ang.…”

Section: Kwas Moczowy a łUszczycaunclassified

Effects of hyperuricemia on the skin

Owczarczyk‐Saczonek¹,

Krajewska–Włodarczyk²,

Placek³

2017

View full text Add to dashboard Cite

StrESzczEniEKwas moczowy jest końcowym produktem metabolizmu puryn, a jego stężenie w surowicy u osób zdrowych wynosi 3-7 mg/dl. Hiperurykemia wiąże się z wyższym ryzykiem wystąpienia incydentów sercowo-naczyniowych, a wzrost stężenia kwasu moczowego, zależny od nieprawidłowych nawyków żywieniowych, jest charakterystyczny dla populacji krajów wysoko rozwiniętych. Hiperurykemia może prowadzić do pojawiania się na skórze różnych zmian chorobowych. Jednocześnie kwas moczowy jest ważnym przeciwutleniaczem, odpowiedzialnym za 2/3 pojemności antyoksydacyjnej organizmu. W pracy przedstawiono zmiany skórne towarzyszące dnie moczanowej (guzki dnawe, "dna prosówkowa", dnawe zapalenie tkanki podskórnej). Dokonano także przeglądu piśmiennictwa i omówiono znaczenie hiperurykemii w łuszczycy. Świadomość i wiedza dermatologów na temat hiperurykemii może wpłynąć na szybsze rozpoznawanie zaburzeń metabolicznych u pacjentów na podstawie oceny skóry. AbStrActUric acid is a final product of purine metabolism, and its concentration in the blood serum of healthy individuals is 3-7 mg/dl. Hyperuricemia is associated with higher cardiovascular risk, and its prevalence related to nutrition profile is characteristic for highly developed societies. It can lead to the appearance of certain skin lesions. On the other hand, uric acid is an important antioxidant, which is responsible for 2/3 of the antioxidant capacity of the body. In this article, the authors present skin lesions associated with gout (tophi, "miliarial gout", gouty panniculitis) and review the data of the literature and discuss the importance of hyperuricemia in psoriasis. Dermatologists' awareness and knowledge about hyperuricemia may favor a faster diagnosis of this metabolic disorder based on skin lesions. WPrOWAdzEniEKwas moczowy (ang. uric acid -UA) jest końco-wym produktem metabolizmu puryn pochodzących z diety, syntezy de novo oraz rozpadu komórek. Puryny są rozkładane przez szereg enzymów, tworzą ksantynę i hipoksantynę, które następnie są utleniane przez oksydazę ksantynową do kwasu moczowego. Stężenie kwasu moczowego w surowicy u osób zdrowych wynosi 3-7 mg/dl (180-420 µmol/l) i jest

show abstract

C-Reactive Protein and Uric Acid Levels in Patients with Psoriasis

Cited by 48 publications

References 10 publications

Biochemical markers of psoriasis as a metabolic disease

Biochemical markers of psoriasis as a metabolic disease

Systemic inflammation, oxidative stress and apolipoprotein B/A1 ratio in active psoriasis: bridging an apparent paradox

Effects of hyperuricemia on the skin

Contact Info

Product

Resources

About